Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Exelixis (EXEL) , which belongs to the Zacks Medical - Biomedical and Genetics industry, could be a great candidate to consider.When looking at the last two reports, this drug developer has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 69.47%, on average, in the last two quarters.For the last reported qu ...